Roivant Sciences Ltd. (ROIV) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Roivant Sciences Ltd. (ROIV) posted $8.26M in revenue for fiscal 2026 (down 71.6% year over year), with a net loss of $299.77M, and has compounded revenue about -19.1%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Roivant Sciences Ltd.
Roivant Sciences Ltd. has grown revenue from $23.80M to $8.26M over the last 6 fiscal years, compounding about -19.1% a year. The most recent year was down 71.6%, so growth has cooled from its longer-run pace.
Net margin sits at -3629.2%, down 3037.2 points year over year.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Roivant Sciences Ltd.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Roivant Sciences Ltd. revenue & earnings — last 6 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $23.80M | $55.29M | $61.28M | $124.80M | $29.05M | $8.26M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-809.23M | $-845.26M | $-1.01B | $4.35B | $-171.98M | $-299.77M |
| Net margin | -3400.9% | -1528.9% | -1646.6% | 3484.9% | -592.0% | -3629.2% |
Source: Roivant Sciences Ltd. SEC filings (10-K).
Roivant Sciences Ltd.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -3629.2%).
Explore 6 years of Roivant Sciences Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ROIV in your portfolio →
Roivant Sciences Ltd. financial history by metric
Compare Roivant Sciences Ltd. with peers
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd. — frequently asked questions
What is Roivant Sciences Ltd.'s revenue?
Roivant Sciences Ltd. (ROIV) reported revenue of $8.26M for fiscal year 2026, down 71.6% from the prior year, according to its SEC filings.
Is Roivant Sciences Ltd. profitable?
No — ROIV reported a net loss of $-299.77M in fiscal 2026.
What is ROIV's P/E ratio?
Roivant Sciences Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Roivant Sciences Ltd. growing?
ROIV's revenue grew at roughly -19.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Roivant Sciences Ltd. have?
As of fiscal year 2026, ROIV carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Roivant Sciences Ltd.'s market cap?
Roivant Sciences Ltd. (ROIV) has a market capitalization of about $20.46B, based on the latest data in our nightly-refreshed cache.
When does Roivant Sciences Ltd.'s fiscal year end?
ROIV's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
Where does this data come from?
All figures are computed from Roivant Sciences Ltd.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.